COMPARISON OF THE VASODILATOR PRAZOSIN AND THE SELECTIVE BETA<sub>1</sub> AGONIST PRENALTEROL ON REST AND EXERCISE HAEMODYNAMICS IN CHF

Prazosin is an orally active post-synaptic selective alpha 1-adrenoreceptor antagonist that has been widely used in treating hypertension and congestive heart failure (CHF). Its role in the treatment of hypertension has previously been reviewed in this journal. Subsequent reports confirm its efficacy in treating mild to severe hypertension as a single agent or, more frequently, in combination with another antihypertensive agent and/or a diuretic. Recent studies of the metabolic effect of prazosin indicate that the drug may have a favourable effect on plasma lipids in hypertensive patients. Its recent use in treatment of congestive heart failure has shown prazosin to be comparable with nitroprusside in producing balanced arterial and venous dilation with generally sustained haemodynamic and clinical effects during long term therapy. Initial studies in Raynaud's phenomenon and in patients with aortic regurgitation or aortic stenosis or with mitral regurgitation are promising, but require confirmation from wider clinical experience. The drug has generally been well tolerated. The primary side effect of orthostatic hypotension can be largely avoided by beginning treatment with a low dose.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

COMPARISON OF THE VASODILATOR PRAZOSIN AND THE SELECTIVE BETA₁ AGONIST PRENALTEROL ON REST AND EXERCISE HAEMODYNAMICS IN CHF

Cited by 2 publications

References 15 publications

The effects of beta1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease

The effects of beta1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease

Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure

Contact Info

Product

Resources

About

COMPARISON OF THE VASODILATOR PRAZOSIN AND THE SELECTIVE BETA1 AGONIST PRENALTEROL ON REST AND EXERCISE HAEMODYNAMICS IN CHF

Cited by 2 publications

References 15 publications

The effects of beta1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease

The effects of beta1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease

Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure

Contact Info

Product

Resources

About

COMPARISON OF THE VASODILATOR PRAZOSIN AND THE SELECTIVE BETA₁ AGONIST PRENALTEROL ON REST AND EXERCISE HAEMODYNAMICS IN CHF